Compare Smith & Nephew plc (SNN) vs Invesco S&P 500 Momentum ETF (SPMO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Smith & Nephew plc vs Invesco S&P 500 Momentum ETF — how do they compare? Smith & Nephew plc trades at $27.72 (market cap $11.63B), while Invesco S&P 500 Momentum ETF trades at $150.46. The key difference: Smith & Nephew plc pays a 2.85% dividend while Invesco S&P 500 Momentum ETF pays none, and Invesco S&P 500 Momentum ETF is trading nearer its 52-week high, Smith & Nephew plc nearer its low. Which is the better fit depends on your goals.
| SNN | SPMO | |
|---|---|---|
Market Cap | $11.63B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $38.53 | $161.66 |
52-Week Low | $27.80 | $107.84 |
Enterprise Value | $14.66B | — |
Dividend Yield | 2.85% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Smith & Nephew (SNN) trades at $27.87, down 3.46% over 24 hours and near its 52-week low. The stock shows a bearish technical trend with mixed sentiment; recent earnings have mostly beaten expectations, but Q2 2026 revenue growth missed and guidance was cut. Fundamentals are solid with revenue rising to $6.16B in 2025 and net income margin improving to 10.08%, though debt levels have increased. The company faces competitive pressures in key markets like U.S. Orthopaedics.
Outlook is cautious: valuation ratios like P/E of 18.96 are reasonable, but analyst consensus is Hold (65%) due to execution risks and CFO departure. Opportunities include innovation in surgical robotics and new product launches, but investors should monitor U.S. market weakness and debt management for sustained recovery.
SPMO trades at $150.47, up 0.5% with a bullish technical outlook supported by strong moving average signals. The ETF has delivered exceptional performance, averaging 37% annual returns over three years according to The Motley Fool (2026-09-06). Recent momentum factor strength and concentrated tech exposure drive its market-beating track record, though this introduces higher volatility during sector rotations.
The outlook remains positive with structural momentum advantages and lower drawdowns than the S&P 500. Key risks include concentrated technology sector exposure and sensitivity to market rotations. Analyst sentiment leans bullish with multiple buy recommendations citing the ETF's rules-based momentum strategy and cost efficiency at 0.13% expense ratio.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →About Invesco S&P 500 Momentum ETF
SPMO is designed to track the investment results of the S&P 500 Momentum Index. This index measures the performance of stocks in the S&P 500 that exhibit the highest momentum, or the greatest price appreciation, over the trailing 12 months, while excluding the most recent month. By investing in these high-momentum stocks, SPMO seeks to capitalize on the historical trend that stocks with strong recent performance tend to continue that performance in the near term, offering a systematic approach to factor investing within the large-cap U.S. equity market.
Read more on SPMO →
